Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1997 1
1998 1
2016 2
2017 5
2018 4
2019 4
2020 8
2021 7
2022 3
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for Maurice J. liver
Search for Maurice J. Lyver instead (1 results)
Non-alcoholic fatty liver disease.
Maurice J, Manousou P. Maurice J, et al. Clin Med (Lond). 2018 Jun;18(3):245-250. doi: 10.7861/clinmedicine.18-3-245. Clin Med (Lond). 2018. PMID: 29858436 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of about 25%. Incidence is increasing with rising levels of obesity, type 2 diabetes and the metabolic syndrome, and NAFLD is predicted to become the leading cause of cirrhosis requiring liver transpl …
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of about 25%. Incidence is increasing with rising levels of obesity …
Response.
Maurice JB, Manousou P. Maurice JB, et al. Clin Med (Lond). 2018 Oct;18(5):440. doi: 10.7861/clinmedicine.18-5-440. Clin Med (Lond). 2018. PMID: 30287450 Free PMC article. No abstract available.
The stratification of cirrhosis.
Maurice J, Pinzani M. Maurice J, et al. Hepatol Res. 2020 May;50(5):535-541. doi: 10.1111/hepr.13493. Epub 2020 Mar 5. Hepatol Res. 2020. PMID: 32072721 Review.
Cirrhosis is traditionally seen as an irreversible stage of chronic liver disease although its clinical course may last several years. ...Other clinical aspects that have a major impact on the quality of life and the possibility of liver transplantation are also dis …
Cirrhosis is traditionally seen as an irreversible stage of chronic liver disease although its clinical course may last several years …
Precision medicine in primary sclerosing cholangitis.
Maurice JB, Thorburn D. Maurice JB, et al. J Dig Dis. 2019 Jul;20(7):346-356. doi: 10.1111/1751-2980.12788. Epub 2019 Jul 3. J Dig Dis. 2019. PMID: 31099965 Review.
There is currently no treatment for the disease, resulting in high rates of advanced liver disease leading to death or liver transplantation. However, advances have been made in our understanding of the pathophysiological mechanisms of the disease, particularly from …
There is currently no treatment for the disease, resulting in high rates of advanced liver disease leading to death or liver t …
Recent advances in liver transplantation.
Burke NT, Maurice JB, Nasralla D, Potts J, Westbrook R. Burke NT, et al. Among authors: maurice jb. Frontline Gastroenterol. 2021 Apr 21;13(1):57-63. doi: 10.1136/flgastro-2020-101425. eCollection 2022. Frontline Gastroenterol. 2021. PMID: 34970429 Free PMC article.
Liver transplant is a life-saving treatment with 1-year and 5-year survival rates of 90% and 70%, respectively. ...
Liver transplant is a life-saving treatment with 1-year and 5-year survival rates of 90% and 70%, respectively. ...
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
Trainee Collaborative for Research and Audit in Hepatology UK. Electronic address: oliver.tavabie@nhs.net; Trainee Collaborative for Research and Audit in Hepatology UK. Trainee Collaborative for Research and Audit in Hepatology UK. Electronic address: oliver.tavabie@nhs.net, et al. J Hepatol. 2023 Oct;79(4):e165-e167. doi: 10.1016/j.jhep.2023.05.035. Epub 2023 Jun 12. J Hepatol. 2023. PMID: 37315808 No abstract available.
Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.
Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Maurice JB, et al. AIDS. 2017 Jul 17;31(11):1621-1632. doi: 10.1097/QAD.0000000000001504. AIDS. 2017. PMID: 28398960 Review.
OBJECTIVE: To identify the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and fibrosis in HIV-monoinfected patients. ...Patients with high BMI [mean difference (MD) 1.38, 95% CI 0.04-2.71 P = 0.04], fasting gluc …
OBJECTIVE: To identify the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NAS …
How to manage alcohol-related liver disease: A case-based review.
Maurice JB, Tribich S, Zamani A, Ryan J. Maurice JB, et al. Frontline Gastroenterol. 2023 May 11;14(5):435-441. doi: 10.1136/flgastro-2022-102270. eCollection 2023. Frontline Gastroenterol. 2023. PMID: 37581189 Free PMC article. No abstract available.
Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.
Nicoletti A, Maurice JB, Thorburn D. Nicoletti A, et al. Among authors: maurice jb. Frontline Gastroenterol. 2020 Mar 2;12(1):62-66. doi: 10.1136/flgastro-2019-101343. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 33456743 Free PMC article. Review.
The current lack of effective pharmacological treatments to prevent progression of liver fibrosis to cirrhosis limits our ability to modify the natural history of the disease. However, a personalised approach and structured follow-up could allow earlier diagnosis and manag …
The current lack of effective pharmacological treatments to prevent progression of liver fibrosis to cirrhosis limits our ability to …
Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis.
Saffioti F, Hall A, de Krijger M, Verheij J, Hübscher SG, Maurice J, Luong TV, Pinzani M, Ponsioen CY, Thorburn D. Saffioti F, et al. Among authors: maurice j. Liver Int. 2021 Nov;41(11):2681-2692. doi: 10.1111/liv.14979. Epub 2021 Jul 13. Liver Int. 2021. PMID: 34051052
Quantitative liver fibrosis assessment by collagen proportionate area (CPA) measurement has been demonstrated to correlate with clinical outcomes in chronic hepatitis C, alcohol-related and non-alcoholic fatty liver disease. ...We assessed the correlations between C …
Quantitative liver fibrosis assessment by collagen proportionate area (CPA) measurement has been demonstrated to correlate with clini …
38 results